Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) PT at $80.92

Immunocore Holdings plc (NASDAQ:IMCR) has been given a consensus rating of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $80.92.

Several analysts recently weighed in on IMCR shares. Guggenheim restated a “buy” rating and set a $92.00 price target on shares of Immunocore in a report on Tuesday, April 23rd. Oppenheimer reiterated an “outperform” rating and issued a $87.00 price target (up previously from $85.00) on shares of Immunocore in a report on Thursday, February 29th. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Immunocore in a research report on Wednesday, March 6th. Canaccord Genuity Group raised their price objective on Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a research report on Thursday, February 29th. Finally, Mizuho boosted their price target on Immunocore from $86.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th.

Immunocore Stock Up 0.7 %

Shares of IMCR stock opened at $59.46 on Tuesday. The company’s fifty day simple moving average is $61.68 and its two-hundred day simple moving average is $60.94. Immunocore has a 52 week low of $42.21 and a 52 week high of $76.98. The stock has a market cap of $2.96 billion, a P/E ratio of -51.26 and a beta of 0.92. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The firm had revenue of $70.16 million for the quarter, compared to analysts’ expectations of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The business’s quarterly revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.63) EPS. Analysts predict that Immunocore will post -1.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunocore

Large investors have recently modified their holdings of the company. Bellevue Group AG boosted its stake in Immunocore by 4,817.1% in the fourth quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after acquiring an additional 956,204 shares in the last quarter. Braidwell LP lifted its stake in shares of Immunocore by 93.8% in the 3rd quarter. Braidwell LP now owns 906,973 shares of the company’s stock worth $47,072,000 after acquiring an additional 438,946 shares during the period. Wellington Management Group LLP lifted its position in Immunocore by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock valued at $294,638,000 after purchasing an additional 399,201 shares during the period. First Turn Management LLC purchased a new stake in shares of Immunocore in the fourth quarter valued at approximately $23,439,000. Finally, Polar Capital Holdings Plc boosted its position in shares of Immunocore by 490.5% during the 3rd quarter. Polar Capital Holdings Plc now owns 250,000 shares of the company’s stock worth $12,975,000 after purchasing an additional 207,664 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.